Navigation Links
Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Date:10/25/2007

tor for AGEs) signaling in an in vivo model of diabetes. He used two drugs aminoguanidine, a well characterized inhibitor of AGE formation, and alagebrium, a novel compound that acts as an AGE-crosslink breaker. The study showed that diabetes resulted in an accumulation of serum AGEs and that there was a 50% reduction in myenteric nNOS expression which was reversible by either aminoguanidine or alagebrium. This is the first reported evidence for the potential importance of AGE signaling in the pathogenesis of enteric neuropathy. In this study, late administration of alagebrium reduced serum AGEs to control levels and also restored nNOS levels. Further studies will be needed to understand the mode of action of alagebrium, however, the results of the study suggest that countering the AGE-RAGE signaling pathway may be a major target for diabetes related gastrointestinal complications, particularly those that arise from reduction of nNOS expression.

"I am quite enthused by the observation that alagebrium may preserve nNOS activity, which would allow it to advance as a leading candidate for clinical development in the fight against this challenging disease," said Dr. Pasricha.

Patients with diabetes commonly experience gastric and intestinal dysfunction, however, the mechanism of how this happens is not well understood. The term diabetic enteropathy is often used to explain the disturbance in bowel function such as chronic diarrhea which occurs in 15% or more diabetics. A role for decreased nNOS expression has been suggested as a possible cause for the diarrhea however how diabetes causes such changes in nNOS expression levels is unknown. Dr. Raj Kumar will continue to work on how glycation of nNOS affects its structure and function.

"Dr. Pasricha's ground breaking work may be the first step in providing treatment for gastrointestinal disorders resulting from diabetes," said Noah Berkowitz, M.D., Ph. D. President and Chief Executive Officer of Synvista.
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... , July 3, 2015 ... adquisición del 100% de participación en ZAO "Biocom" ... adquisición marca la incursión de Lupin en el ... de RUB en ventas, colocándolo como uno de ... 2014 (IMS Health). Durante más de una década, ...
(Date:7/2/2015)... N.C. , July 2, 2015  New product ... of its leading role in educating thought leaders about ... that can heavily influence how well a new therapy ... new study from research and consulting leader Best Practices, ... leaders need to focus on are early stage thought ...
(Date:7/2/2015)... -- According to a new market research report ... Cord Stimulation, Transcranial Magnetic Stimulation), Application (Depression, Parkinson,s, Tinnitus, Alzheimer,s, ... by MarketsandMarkets, the global Neuromodulation Market is estimated at $3.65 ... by 2020, at a CAGR of 11.2% during the forecast ... market data T ables and ...
Breaking Medicine Technology:Lupin adquiere Biocom en Rusia 2Lupin adquiere Biocom en Rusia 3Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Neuromodulation Market Worth $6.20 Billion by 2020 2Neuromodulation Market Worth $6.20 Billion by 2020 3Neuromodulation Market Worth $6.20 Billion by 2020 4
... Rescue Riders, a national volunteer organization dedicated to giving ... has selected the HeartSine® samaritan® PAD Automated External Defibrillator (AED) for ... , , ... in 40 states who are trained as first responders for roadside ...
... , , , ... 3 Recently, researchers have observed a disturbing trend in neonatal units across ... to treat premature infants. This alarming development has raised serious concerns from many consumer ... , , ...
Cached Medicine Technology:Motorcyclist Volunteers Come to the Rescue With HeartSine AEDs 2Spike in Use of Popular Reflux Drug to Treat Infants Causes Alarm 2
(Date:7/3/2015)... ... ... Scientists at several top US cancer centers believe they now know why ... here to read the complete story , just posted on the Surviving Mesothelioma website. ... and New York University exposed mice with a mutation on the tumor suppressor gene ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. ... has been retained to lead a national president recruitment for Regional ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
(Date:7/3/2015)... ... July 03, 2015 , ... ... place on June 25, 2015 at 1:00pm. The Association welcomed speaker C. Daniel ... to injured bicyclists and practical points of investigating these types of cases. , ...
(Date:7/3/2015)... ... July 03, 2015 , ... Talcum powder attorneys representing clients in national ... Powder Cancer Lawsuit Center website. Just as the previous version did, the new website ... timely lawsuit updates and ovarian cancer warning information. The site is routinely updated with ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room , the ... Manzanares, MD as the new Medical Director of its Frisco facility. , “We are ... Frisco facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
Breaking Medicine News(10 mins):Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3
... health care, study suggests, , TUESDAY, Aug. 11 (HealthDay News) ... to the doctor, but new research finds they,re especially likely ... Middle-aged men who are most devoted to traditional beliefs about ... routine medical care, researchers report. , It,s not clear whether ...
... , , , ... of Paul Davis to the corporate management team as the National Sales ... the management team, developed as a result of the rapid growth of ... our sales force reflects the tremendous growth eCardio has experienced in the ...
... , , WASHINGTON, Aug. 11 ... Gurney, the founder and publisher of the Guide to Retirement ... of Thomas Circle, a downtown Washington, D.C. retirement community. Gurney is ... , During the last 20 years, Gurney has immersed ...
... ... Clarity Viewer via Internet Access , ... (PRWEB) August 11, 2009 -- iCRco releases the latest version of its affordable and ... the growth of Computed Radiography for medical imaging there has been an increased need for ...
... , , , ... school, make sure they,re getting the nutritious breakfast they need for the ... high-quality protein breakfast like eggs can help them stay more focused in ... Board, 52 percent of moms serve hard-cooked eggs for breakfast because of ...
... , , Awarded $100,000 ... Practicing Physicians Named Runners-Up, also Awarded Cash Prizes , , ... has been awarded the prestigious J.H. Kanter Prize for his exceptional work to ... Boston. , , The inaugural prize, named for Joseph ...
Cached Medicine News:Health News:For Macho Men, Doctor Visits Are Less Likely 2Health News:eCardio Diagnostics Expands Corporate Management Team 2Health News:Middle-Aged Senior Care Advocate to Move Into D.C. Retirement Community 2Health News:iCRco Releases Clarity PACS, a New Approach to Managing Digital Imaging Data 2Health News:iCRco Releases Clarity PACS, a New Approach to Managing Digital Imaging Data 3Health News:Start the School Year Off Right With an Eggcellent Breakfast 2Health News:Start the School Year Off Right With an Eggcellent Breakfast 3Health News:Dr. James O'Connell Named J.H. Kanter Prize Laureate 2Health News:Dr. James O'Connell Named J.H. Kanter Prize Laureate 3
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Antigenic Free Protein S, ELISA Method...
Immuno-turbidimetric Assay for Antithrombin III Antigen. Suspension of microlatex particles coated with specific antibodies....
... Colorimetric Assay of ... and Low Molecular ... substrate CBS 31.39, ... purified bovine ATIII, ...
Medicine Products: